- Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
- Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
- Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
- Anaptys Named a BioSpace 2024 Best Places to Work Winner
- Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
- Anaptys Announces Participation in November Investor Conferences
- Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
- Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
- Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
More ▼
Key statistics
On Monday, AnaptysBio Inc (ANAB:NSQ) closed at 19.66, 47.16% above the 52 week low of 13.36 set on Nov 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.93 |
---|---|
High | 20.27 |
Low | 19.60 |
Bid | 15.00 |
Offer | 31.98 |
Previous close | 19.87 |
Average volume | 329.48k |
---|---|
Shares outstanding | 26.76m |
Free float | 26.66m |
P/E (TTM) | -- |
Market cap | 526.16m USD |
EPS (TTM) | -6.07 USD |
Data delayed at least 15 minutes, as of Apr 22 2024 21:00 BST.
More ▼